Ann: Placement and Entitlement Offer to raise up to $7.1 million, page-50

OncoSil has been approved in a total of 35 countries across the World in 3 years. OncoSil can now be used across the European Union (E.U), the United Kingdom (U.K), New Zealand, Hong Kong, Singapore, Switzerland, Turkey, Israel, and Malaysia. This means more OncoSil treatments will be sold across the world, boosting revenues (that perform well) and the share price over time. However, while they have developed strong partnerships with hospitals in Spain, the UK, Israel, etc, they need to train doctors for them to use the device effectively. Revenues are up 43% since 2021, so I think it's good for the company and shareholders IMO